A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
アムジェン株式会社(本社:東京、代表取締役社長:スティーブ・スギノ、以下「当社」)は、当社の乾癬疾患啓発活動のパートナーであるお笑いタレントの「フットボールアワー」のお二人をMCにお迎えして、乾癬患者さんと医師が乾癬と乾癬診療に対してお互いに知りたいこと・伝えたいことを「本音」で意見交換する「乾癬TV」の動画を制作しました。本動画は2021年11月10日(水)より、当社の乾癬患者さん向けWebサイト「乾癬パートナーズ」(https://www.kansen-partners.jp/)で公開します。
「乾癬TV」では、「フットボールアワー」のお二人によるMCのもと、乾癬患者さんと医師が腹蔵なく「本音」を語り合うことのできる機会を提供し、患者さんが本当に知りたいこと・医師が本当に伝えたいことを発見していくと共に、乾癬に対する正しい知識を学ぶことができます。動画の第一部では、患者さんが実生活で困ったときのエピソードを紹介していただきます。第二部では、「患者と医師の本音トークコーナー」として、患者さんが知りたいこと・医師が伝えたいことを語り合っていただきます。現在の乾癬治療に対する満足度や、主治医とのコミュニケーションに対する満足度について触れながら、患者さんと医師の間に存在すると言われているコミュニケーションギャップ1,2について話し合い、両者が「本音」で解決策を探っていきます。
当社では、乾癬に対する正しい知識の普及を目指して、これまでにも様々な取り組みを行ってまいりました。その一つとして、当社の乾癬疾患啓発活動のプラットフォームとして、LINEヘルスケア株式会社と共同でLINE公式アカウント「乾癬@LINEヘルスケア」を開設しました。また、毎年10月29日の「世界乾癬デー」に関連した取り組みとして、乾癬に対する基礎知識を深めるWebコンテンツ「KANSEN TEST」を実施しています。
今回公開するWeb動画「乾癬TV」は、乾癬患者さんと医師の間に存在すると言われているコミュニケーションギャップ1,2を解消し、両者のより良いコミュニケーションをサポートすることで、医師と患者さんが乾癬診療のより強固な「パートナー」になるための一助となることを目指して制作しました。
【乾癬TV概要】
公開日:2021年11月10日(水)
動画URL:https://www.kansen-partners.jp/footballhour
内容:
第一部…「乾癬患者さんのエピソードトーク」
第二部…「患者と医師の本音トークコーナー」
アムジェン株式会社では、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、今後も患者さんの生活や治療をトータルサポートするための活動に取り組み、乾癬患者さんお一人お一人の前向きな生活と治療を後押ししてまいります。
尋常性乾癬について
乾癬は、免疫反応の異常によって発症する全身性の慢性炎症性疾患です3,4。日本における罹患者は40~50万人以上と推計されています5,6。乾癬は主に5つの病型に分かれますが、尋常性乾癬が最も多くみられる病型で、乾癬患者さんの約90%を占めています7。銀白色の鱗屑に覆われた境界鮮明な紅班が特徴です。乾癬の症状は、肘や膝などの関節付近で確認されることが多く、頭皮や爪にも症状が現れることがあります。また84%の患者さんが痒みを感じているという報告もあります8。こうした状況は、QOLに悪影響が及んでいると考えられ、乾癬患者さんの身体的項目や精神的項目のQOLでは、がんや心筋梗塞の患者さんより低いとする報告もあります9。
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。2013年10月にアステラス製薬との合弁会社であるアステラス・アムジェン・バイオファーマとして事業を開始し、2020年4月1日にアムジェン社の完全子会社となり商号を変更しました。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、現在約600人の従業員が、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。
アムジェン社について
アムジェン社は、重篤な疾患に苦しむ患者さんのために、生物学的に革新的な治療を探索・開発・製造・提供する可能性を切り拓いていきます。このアプローチは、疾患の複雑性の解明と人体の生物学上の基本を理解するために、先進的なヒト遺伝学などの手法を活用することから始まります。
アムジェン社は、アンメット・メディカル・ニーズが大きい領域に焦点を絞り、生物製剤の製造に関する専門知識を活用して医療効果の向上と人々の生活に画期的な改善をもたらすソリューションを追求しています。1980年に創業したバイオテクノロジーのパイオニアであるアムジェン社は、世界最大の独立バイオテクノロジー企業に成長し、世界中の多くの患者さんに貢献しており、革新的な可能性が期待されるパイプラインを開発しています。
詳細についてはwww.amgen.comをご覧になるか、www.twitter.com/amgenをフォローしてください。
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.
注意事項(アムジェン株式会社)
このニュースリリースに含まれている医薬品(開発中のものを含む)に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社(東京)
コーポレート・アフェアーズ
TEL 03-4590-1771
REFERENCE